R&D News | pharmaphorum

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

News

Dr Andrew Anzalone, Prime Medicine co-founder and head of platform development

Gene-editing firm Prime Medicine files $140m public offer

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic d

News

Exercise ‘may be better than drugs for depression’

Doctors should think twice before prescribing drug therapies when faced with someone battling depression, as exercise may be more effective, according to a new study.

AZ, Daiichi eye December verdict for TROP2 ADC

Gilead’s CD47 woes continue, this time in solid tumours

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Freenome raises $254m for cancer tests, and other financings

Gene-editing firm Prime Medicine files $140m public offer

Exercise ‘may be better than drugs for depression’

FDA declines to approve AbbVie's Botox follow-up

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks